Carl Zeiss Meditec AG

  • WKN: 531370
  • ISIN: DE0005313704
  • Land: Deutschland

Nachricht vom 14.05.2003 | 07:00

Carl Zeiss Meditec AG english

Carl Zeiss Meditec AG: Sales increase by 35.6 percent

Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
-----
---EBIT at EUR 11.1m more than doubled after first six months---

(Jena, 14 May 2003) In the first half of the 2002/2003 financial year Carl
Zeiss
 Meditec AG significantly increased its sales and net income. The sales
volume
rose by 35.6% to EUR 124.1m. Compared to the same period last year,
operating
income (EBIT) grew by 104.1% to EUR 11.1m (previous year: EUR 5.5m). The
increase in profits was partly attributable to the improved gross margin
and a
healthy growth in sales.

Seen on a quarterly basis (1.1.-31.3.) there was also a significant
increase in
sales and profits: sales improved by 36.4% to EUR 61.7m (previous year: EUR
45.3m) and EBIT grew by 26.0% to EUR 5.3m (previous year: EUR 4.2m).

In the past six months the cash and cash equivalents increased by 89.3% to
EUR
13.6m. Operative cash flow reached the level of EUR 6.2m. The equity ratio
increased from 49.2% (as of 30 September 2002) to 50.0%. With the disposal
of
the Aesthetic and Dental business segments immediately after the end of the
reporting period the process of focusing on ophthalmic business was
brought to a
 completion.

(The financial statements according to US GAAP are only to a limited extent
comparable with the previous years' figures, as they relate exclusively to
the
former Carl Zeiss Ophthalmic Systems AG and do not include the former
Asclepion-
Meditec AG.)

Contact:
Carl Zeiss Meditec AG, Jens Brajer/Investor Relations, Goeschwitzer Str.
51 -
52, D-07745 Jena, Telephone +49 (0)3641-220-105, Fax: +49 (0)3641-220-117,
E-
mail: investors@meditec.zeiss.com

end of ad-hoc-announcement  (c)DGAP 14.05.2003
---------------------------------------------------------------------------
-----
WKN: 531370; ISIN: DE0005313704; Index:
Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in
Berlin-
Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart

140700 Mai 03

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

Syzygy AG: Aktie kaufen

Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.

Event im Fokus

38. m:access Analystenkonferenz München

Datum: 06.06.2013
Zeit: 9:30 Uhr - 17.00 Uhr
Ort: Börse München



Aktuelle Research-Studie

Original-Research: getgoods.de Anleihe (von GBC AG): stark überdurchschnittlich attraktiv getgoods.de Anleihe

24. Mai 2013